|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results uncover a differential response to ibrutinib between cell lines and the CLL clone and imply that ibrutinib could differ from idelalisib in their potential to induce AID in treated patients.
|
30814061 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In chronic lymphocytic leukemia (CLL) increased expression of alternatively spliced AID variants has been documented.
|
30368590 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Next, we tested the cancer-cell specificity of a therapeutic compound using the MEC1 cell line, a chronic lymphocytic leukemia (CLL) cell line that expresses activation induced cytidine deaminase (AID).
|
30183475 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistently, PI3Kδ inhibitors enhanced AID expression and translocation frequency to IGH and AID off-target sites in human chronic lymphocytic leukaemia and mantle cell lymphoma cell lines, and patients treated with idelalisib, but not ibrutinib, showed increased somatic hypermutation in AID off-targets.
|
28199309 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AID expressions were increased in patients with CLL.
|
28388279 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In line with this, we found that clustered mutations (kataegis) in lymphoma and chronic lymphocytic leukemia predominantly carry AID-hotspot mutational signatures.
|
25486549 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results show that AID expression may be associated with deletions in patients with CLL.
|
23662991 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations found in CLL followed the features of canonical somatic hypermutation mechanism: preference of targeting for activation-induced cytidine deaminase and polymerase motifs, base change bias for transitions and more replacement mutations occurring in CDRs than in framework regions.
|
24725733 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a proof of principle, we show that DIDS treatment inhibits repair of AID-initiated DNA breaks, induces apoptosis, and promotes cytotoxicity preferentially in AID-expressing human CLL.
|
23589568 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, this possibility has been questioned in CLL because the number of circulating AID mRNA(+) cells is exceedingly low; synthesis of AID protein by blood CLL cells has not been demonstrated; the full range of AID functions is lacking in unmutated CLL (U-CLL), and no prospective analysis linking AID expression and disease severity has been reported.
|
23071276 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, we found that the mRNA levels of patients with AID in CLL were eight-fold higher than those in control patients, suggesting that AID overexpression promotes chromosomal abnormalities and is associated with CLL progression and survival.
|
21133730 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The available data on AID-mRNA splicing patterns in CLL are limited and conflicting.
|
20117026 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous work has shown expression in peripheral blood (PB) of CLL B cells of activation-induced cytidine deaminase (AID) among CLL patients with an unmutated (UM) profile of immunoglobulin genes and with ongoing class switch recombination (CSR) process.
|
20233972 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the first patient (harboring the unmutated IgVH locus) a significant bias to point mutations at CG pairs (21/25; P=0.009), their remarkable preference for the RGYW/WRCY motives (28%) and the highest expression of the activation-induced cytidine deaminase (AID) mRNA among the 34 tested B-CLL samples.
|
17920683 |
2008 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The involvement of AID in the progression of leukemia has been suggested by multiple groups on the basis of observations of the statistical correlation between AID expression and a poor prognosis of B-cell chronic lymphocytic leukemia.
|
16720548 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that AID expression and ASHM are associated with higher-grade transformation of CLL and provide further evidences that AID expression and ASHM may be activated during the clonal history of B-cell lymphomas.
|
16541139 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AID expression in the CLL cases was weak with slight variations regardless of the subgroup affiliation.
|
15902296 |
2005 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As opposed to groups II-III, group I B-CLLs lacked expression of ZAP-70 and activation-induced cytidine deaminase in the majority of cases, while more frequently had mutated IgV(H) genes and IgV(H) mutations consistent with antigen-driven selection.
|
15605425 |
2005 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a recent work we have shown that in contrast to normal circulating B-cells, AID transcripts are expressed constitutively in CLL patients undergoing active CSR, but interestingly this expression occurs predominately in unmutated CLL B-cells.
|
16323428 |
2005 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia.
|
14961036 |
2004 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using 2 specific antibodies, here we show that the AID protein can be detected in GC centroblasts and their transformed counterpart (Burkitt lymphoma) but not in pre-GC B cells and post-GC neoplasms, including B-cell chronic lymphocytic leukemia and multiple myeloma.
|
15304391 |
2004 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a series of 141 B-CLLs, 124 cases were examined for IgV(H) gene per cent mutations and skewing of replacement/silent mutations in the framework/complementarity-determining regions as evidence of antigen-driven selection; this identified three B-CLL subsets: significantly mutated (sM), with evidence of antigen-driven selection, not significantly mutated (nsM) and UM, without such evidence and IgV(H) gene per cent mutations above or below the 2% cut-off. sM B-CLL patients had longer survival within the good prognosis subgroup that had more than 2% mutations of IgV(H) genes. sM, nsM and UM B-CLL were also characterized for the biased usage of IgV(H) families, intraclonal IgV(H) gene diversification, preference of mutations to target-specific nucleotides or hotspots, and for the expression of enzymes involved in SHM (translesion DNA polymerase zeta and eta and activation-induced cytidine deaminase).
|
15198729 |
2004 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigated AID mRNA expression in 20 CLL cases.
|
12586616 |
2003 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Our results show a dissociation between SHM and CSR in CLL and suggest that, in this disease, AID would require additional help for carrying out the SHM process.
|
12521993 |
2003 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results show a dissociation between SHM and CSR in CLL and suggest that, in this disease, AID would require additional help for carrying out the SHM process.
|
12521993 |
2003 |